Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD4+ T-cell receptors specific for TET-P–MHC class II complexes are specialized recognition molecules found on the surface of helper T lymphocytes that specifically bind to peptides derived from the Tetanus toxoid (TET-P) when presented by Major Histocompatibility Complex (MHC) class II molecules. These receptors are fundamental to the adaptive immune response, as their engagement triggers the activation of CD4+ T cells, which then produce essential cytokines such as interferon-gamma (IFN-γ) and interleukin-2 (IL-2). In clinical research and vaccine development, Tetanus helper peptides are frequently utilized as universal epitopes to provide the necessary T-cell help for inducing potent immune responses against other antigens, such as those found in cancer or viral infections. Because a large majority of the human population has been previously immunized against Tetanus, these TCRs represent a pre-existing and readily recruitable population of memory cells that can be leveraged to enhance the efficacy of various therapeutic interventions. Monitoring the frequency and activity of T cells bearing these TCRs serves as a vital biomarker for assessing the immunogenicity and success of vaccine-based therapies.
Activation of CD4+ T cells via TCR-CD3 complex signaling upon recognition of the TET-P–MHC II complex, leading to the secretion of cytokines (IFN-gamma, IL-2) and expression of CD40L, which supports CD8+ T cell and B cell responses.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor specific for Tetanus toxoid peptide-MHC class II complex (Tet-specific TCR).